STOCK TITAN

DENTSPLY SIRONA (XRAY) SEC Filings, Sep-Oct 2025

XRAY NASDAQ

DENTSPLY SIRONA Inc.'s SEC filings document regulatory disclosures for a diversified dental products and technology manufacturer listed on Nasdaq under XRAY. Recent Form 8-K reports furnish operating results, GAAP and non-GAAP reconciliations, outlook commentary, distribution agreements, product and regulatory updates, restructuring actions and capital allocation changes involving dividend policy, debt reduction and share repurchases.

The company's proxy and governance filings cover director elections, board composition, committee assignments, executive compensation and stockholder meeting matters. Other current reports disclose board expansion, director appointments, chief financial officer transition matters, separation arrangements and Regulation FD communications tied to commercial agreements and corporate updates.

Rhea-AI Summary

DENTSPLY SIRONA (XRAY) reported an insider transaction by its EVP & CFO. On 10/10/2025, the officer acquired 556.226 shares (Transaction Code A) at $0. A footnote explains these represent dividend equivalents on previously granted RSUs, issued as additional RSUs that vest on the same schedule as the underlying awards and convert to common stock on a 1:1 basis.

After this transaction, the reporting person beneficially owned 44,011.347 shares, held directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
none
-
Rhea-AI Summary

DENTSPLY SIRONA (XRAY) reported an insider transaction by SVP, CHRO Andrea Frohning. On 10/10/2025, she acquired 357.053 shares of common stock at $0, representing dividend equivalents on previously awarded RSUs that vest with their underlying awards; each RSU converts to common stock on a 1:1 basis.

She also acquired 22.893 shares of phantom stock under the Supplemental Executive Retirement Plan at a $11.98 derivative security price; phantom stock is economically equivalent to common stock and becomes payable in common stock upon termination of employment. Following these transactions, she beneficially owned 33,609.865 shares of common stock directly and 1,736.5455 phantom stock units directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
none
-
Rhea-AI Summary

DENTSPLY SIRONA (XRAY) reported an initial statement of beneficial ownership for executive Aldo Mariano Roberto Denti. The filing notes he serves as EVP, Chief Commercial Officer and indicates no securities are beneficially owned.

The Form 3 lists the Date of Event as 10/06/2025 and was filed by a single reporting person. An Exhibit 24 Power of Attorney is included, with the form signed by an attorney-in-fact on the executive’s behalf.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
none
Rhea-AI Summary

DENTSPLY SIRONA (XRAY) filed a Form 4 for director Willie A. Deese. On 10/10/2025, 179.449 restricted stock units were acquired at $0 under code A as dividend equivalents on existing RSUs. After this entry, beneficial ownership is 57,546.558 shares, held directly. These dividend RSUs follow the same vesting schedule as the underlying awards, with each RSU converting to common stock on a 1:1 basis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
none
-
Rhea-AI Summary

DENTSPLY SIRONA (XRAY) executive Kevin Czerney, VP and Chief Accounting Officer, reported routine equity accruals. On 10/10/2025, he acquired 233.911 RSUs as dividend equivalents at $0, which vest on the same schedule as the underlying RSUs.

Following these transactions, his direct beneficial ownership of common stock is 27,264.0691 shares. The filing notes this includes 112.5060 shares acquired through dividend reinvestment on 10/10/2025.

He was also credited 45.4596 phantom stock units under the SERP and 4.4453 phantom stock units under the DSSP at $11.98 per unit, each economically equivalent to one common share and payable in common stock upon termination of employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
none
-
Form 4
Rhea-AI Summary

DENTSPLY SIRONA (XRAY) director reported an equity change tied to restricted stock units. On 10/10/2025, the reporting person acquired 223.681 RSU dividend equivalents at $0. According to the footnote, these represent dividends on RSUs credited as additional RSUs, vesting on the same schedule as the underlying awards, with each RSU converting to common stock on a 1:1 basis.

Following this transaction, the reporting person beneficially owned 17,699.171 shares, held directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
none
Rhea-AI Summary

DENTSPLY SIRONA announced that the SEC’s Division of Enforcement has concluded its investigation and does not intend to recommend any enforcement action against the company. The inquiry, initiated by the SEC in connection with an internal review led by the Audit and Finance Committee into certain financial reporting matters raised by employees, began in May 2022 and closed on October 14, 2025. The company had voluntarily contacted the SEC and fully cooperated throughout.

The closure removes a regulatory overhang tied to past financial reporting questions and reflects the regulator’s decision not to pursue action. Management characterized the outcome as a significant and favorable development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
current report
-
Rhea-AI Summary

DENTSPLY SIRONA Inc. announced that Richard C. Rosenzweig, Executive Vice President, Corporate Development, General Counsel and Secretary, will step down from that role by mutual agreement effective October 3, 2025. He will serve as a non-executive Special Legal Advisor through a Separation Date no later than March 4, 2026 to transition responsibilities. Under a Transition and Separation Agreement dated October 2, 2025, he is eligible for severance under prior agreements and will receive a monthly fixed fee of $30,000 while Special Legal Advisor; if terminated early without Cause, that amount is payable as if he served through March 4, 2026. After the Separation Date, the Company will engage him as an independent contractor for one year at $20,000 per month. Receipt of these payments is generally contingent on execution of a release and compliance with post-termination covenants. The Transition and Separation Agreement is filed as Exhibit 10.1.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
current report
-
Rhea-AI Summary

Jonathan Jay Mazelsky, a director of DENTSPLY SIRONA Inc. (XRAY), was granted phantom stock units on 09/30/2025. The Form 4 reports an award of 2,386.165 phantom stock units under the directors' deferred compensation plan, with an indicated price of $12.57 per underlying share. Each phantom share is the economic equivalent of one share of common stock and becomes payable in common stock upon the reporting persons termination of service. After the reported award, the Form shows 11,620.2024 shares beneficially owned by the reporting person in a direct ownership form.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
insider
Rhea-AI Summary

DENTSPLY SIRONA Inc. approved a one-time retention equity award to certain executives, including named executive officer Tony Johnson, Senior Vice President and Chief Supply Chain Officer. The award is a stock option grant with a grant date fair value of $2,000,000 awarded to Mr. Johnson to recognize his performance during recent CEO and CFO transitions and to incentivize retention through the next three years.

The options are expected to be granted on the second trading day after the company files its quarterly report for the fiscal quarter ended September 30, 2025, will cliff-vest on the third anniversary of the grant date provided continuous employment, and will expire on the tenth anniversary. Half of the options will have an exercise price equal to the fair market value on the grant date and half will have an exercise price equal to 110% of that value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
current report

FAQ

How many DENTSPLY SIRONA (XRAY) SEC filings are available on StockTitan?

StockTitan tracks 147 SEC filings for DENTSPLY SIRONA (XRAY), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for DENTSPLY SIRONA (XRAY)?

The most recent SEC filing for DENTSPLY SIRONA (XRAY) was filed on November 16, 2026.